Scholar Rock Holding Corp. (SRRK)

Over the past six months, SRRK's stock price has been impacted by several key events. The FDA issued a Complete Response Letter (CRL) for apitegromab in September 2025, which was followed by a resubmission of the Biologics License Application (BLA) in March 2026 after a Type A meeting with the FDA. Scholar Rock reported a positive Q4 2025 earnings beat and a positive Q1 2026 outlook, but also reported a larger net loss in Q1 2026. Analysts have shown strong confidence in the company, with several financial institutions raising their price targets. Scholar Rock strengthened its balance sheet by raising $111.8 million and drawing $200 million under a new term loan facility. Insiders have sold $5.0 million worth of shares, while an independent director exercised options to buy approximately $4.2 million worth of stock.

There is no explicit indication of demand seasonality for Scholar Rock Holding Corp.'s products and services. Demand is primarily driven by medical need, regulatory approvals, and market access, rather than seasonal fluctuations.

Scholar Rock Holding Corp. is a biopharmaceutical company focused on developing innovative medicines for rare, severe, and debilitating neuromuscular diseases, particularly Spinal Muscular Atrophy (SMA). The company discovers, develops, and delivers protein therapeutics that selectively target growth factors involved in disease processes, utilizing a proprietary platform that modulates endogenous growth factor activation within the transforming growth factor beta (TGFβ) superfamily. Its major product candidates include Apitegromab, an investigational monoclonal antibody for SMA, SRK-439, an investigational antibody for other rare neuromuscular diseases, and early-stage pipeline programs aimed at neuromuscular disorders, cancer, and fibrosis.

Scholar Rock Holding Corp. is headquartered in Cambridge, Massachusetts, United States. The company is engaged in both U.S. and European regulatory activities for apitegromab.

Scholar Rock's brand reputation has been influenced by its progress with apitegromab. The Complete Response Letter from the FDA in September 2025 could have raised concerns, but the successful resubmission of the BLA in March 2026 has positively impacted its reputation. The FDA's acceptance of the BLA and the setting of a PDUFA date for September 2026 are seen as crucial regulatory milestones. Analyst upgrades and positive ratings further reflect a strong and improving brand perception. The company's continued investment in its late-stage neuromuscular programs and launch readiness also contributes to a perception of strong operational focus and commitment.

Scholar Rock Holding Corp. has significant institutional ownership, with 281 institutional owners and shareholders holding a total of 122,743,441 shares, including Fmr Llc, BlackRock, Inc., and Samsara BioCapital, LLC. Srinivas Akkaraju is the largest individual shareholder, owning 14.64% of the company's shares, with other notable insiders including Siren LLC, Invus Global Management LLC, and Samsara Biocapital GP LLC.